Foresite Capital was established as a healthcare growth equity company with its head office in San Francisco. The company recently added Dr. Molly He to its leadership team. Dr. He joins Foresite Capital as a venture partner. The company seeks to benefit from her 15 years expertise in pharmaceutical and genomic research.
The current CEO and MD of Foresite Capital, Jim Tananbaum, praised Dr. He for her professional excellence. Tananbaum also pointed out that Dr. He stands out from other scientific researchers due to her mastery of next-generation sequencing. Her extensive scientific research experience and excellent record of leadership will significantly impact the growth of Foresite Capital. The company is in need of such expertise as it diversifies its services and products.
Foresite Capital is renowned for investing in innovative and upcoming ventures in the healthcare industry. Dr. He said that she looks forward to helping in growing Foresite’s next-generation sequencing portfolio. She was instrumental in the initiation of protein reagents improvements and innovation as she worked as Illumina’s senior director of scientific research.
In an article on Fierce Biotech, Dr. Molly He attributes her successful pharmaceutical career to the biochemistry degree she acquired from Nankai University. She has over 20 patented technologies and publications under her name. She also spent a part of her professional career researching on antibody and small molecule drugs for the immune system and cancer diseases.
About Jim Tananbaum
James, popularly called Jim, Tananbaum is one of the executives who played a big role in influencing growth in Foresite Capital. The company celebrates him as its first CEO. Before joining Foresite, Tananbaum founded a pharmaceutical company known as GelTex. The firm was later sold for $1.6B to Genzyme. Jim Tananbaum also worked for Theravance and had shares in Allergen Research Corporation. He is known for facilitating investments in over 21 healthcare companies. These include Amerigroup, Amira Pharmaceuticals, and Jazz Pharmaceuticals.
Jim Tananbaum holds a B.S.E.E and B.S from Yale University and an MBA from Harvard Business School. He also attended Harvard Medical School for an M.D course. He was a member of Harvard and MIT’s HST Program. He also participated on the visiting committee of Yale University. More details can be found on LinkedIn.